

Valgeirsdóttir IR¹, Hildén K¹, Patil S², Simmons D^{2,3}, Schwarcz E¹, de Brun M¹, Montgomery S², Jansson S¹, Berntorp K⁴, Persson M⁵, Storck-Lindholm E⁶, Sengpiel V⁷, Wennerholm UB⁷, Ahlsson F⁸, Wikström AK⁸, Strevens H⁹, Backman H¹.

¹Faculty of Medicine and Health, Örebro University, Sweden. ²School of Medical Sciences, Örebro University, Sweden. ³School of Medicine, Western Sydney University, Campbelltown, Australia.

⁴Department of Clinical Sciences Malmö, Lund University, Sweden. ⁵Department of Clinical Science and Education Karolinska Institute, Sweden. ⁶Department of Obstetrics and Gynecology Södersjukhuset, Karolinska Institute, Sweden. ⁷Sahlgrenska University Hospital and Gothenburg University, Sweden. ⁸Department of Women's and Children's Health, Uppsala University, Sweden.

⁹Department of Clinical Sciences Lund, Lund University, Sweden.

Aim

To evaluate pregnancy outcomes based on different treatment modalities for gestational diabetes mellitus (GDM) with focus on metformin.

Material and method

Observational study based on data from the stepped wedge cluster randomized trial; Changing diagnostic criteria for GDM in Sweden – www.cdc4g.se.

Population was singleton pregnancies during 2018 from eight clusters (approximately 48% of all pregnancies in Sweden in 2018). Screening was based on risk factors and random plasma glucose measurements. Half of the population got GDM diagnosis based on old (overt diabetes) and half based on new (WHO-2013) diagnostic criteria.

Pregnancy outcomes for women with metformin treated GDM, and other treatment modalities, were compared to background population without GDM.

Logistic regression analyzes with adjustments for potential confounders (body mass index, age, smoking, parity, country of birth, chronic hypertensive disease and cluster) for all outcomes.


Introduction

Metformin as treatment for GDM is a matter of controversy. Concerns about the effects on neonatal birth weight (mainly small for gestational age) have been raised.

Results

Of the 54 678 pregnancies included, 2 169 (4.0%) were diagnosed with GDM; of whom 1 076 (49.6%) were treated with diet only, 668 (30.8%) with metformin only, 116 (5.3%) with insulin only, and 309 (14.2%) with both metformin and insulin. Pregnancy outcomes are shown in the figure and table below.

Pregnancy outcomes for metformin (with and without insulin) treated GDM compared to background population.




Pregnancy outcomes for different treatment modalities for GDM.

	Background, reference (n= 52 509) N (%)	Metformin GDM (n=668) aOR	Insulin GDM (n=116) aOR	Metformin & insulin GDM (n=309) aOR
SGA (10th percentile)*	5 886 (11.2)	0.57 (0.41-0.79)	0.48 (0.21-1.09)	0.78 (0.51-1.18)
LGA (90th percentile)*	5 904 (11.3)	2.29 (1.88-2.78)	2.47 (1.58-3.86)	2.32 (1.76-3.07)
Preterm (< 37 gest. wks)	2 322 (4.4)	1.79 (1.30-2.47)	1.36 (0.59-3.13)	1.97 (1.26-3.08)
Neonatal composite*	733 (1.4)	1.46 (0.72-2.98)	3.03 (0.94-9.73)	N/A
Preeclampsia	1 370 (2.6)	1.60 (1.04-2.46)	1.90 (0.69-4.24)	1.37 (0.70-2.70)
Cesarean section	9 402 (17.2)	1.56 (1.29-1.88)	1.10 (0.68-1.77)	1.95 (1.51-2.52)
Induction of labour	10 072 (19.2)	2.64 (2.23-3.13)	4.78 (3.23-7.08)	2.93 (2.30-3.74)

*SGA = small for gestational age. LGA = large for gestational age. Neonatal composite = respiratory distress, birth trauma, stillbirth, neonatal death, need for therapeutic cooling.

Conclusion

These preliminary results show decreased risk for small for gestational age (SGA) birth weight when treating GDM with metformin compared to background population.



inga-ros.valgeirsdottir@oru.se

SCAN ME

